A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality (Faucon, Kidney International 2023)
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality (Faucon, Kidney International 2023)